ArticleNature medicine2018
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Abstract readPublished Erratum
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Trial
- Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma.Frontiers in oncology · 2026Article
- Molecular subtypes of DLBCL: are we ready to translate our knowledge into the change of treatment paradigms?Hematology. American Society of Hematology. Education Program · 2025Review
- Comprehensive Genetic Analysis of Central Nervous System Involvement in Mycosis Fungoides: A Case Report.EJHaem · 2025Article
- Multisite clinical cross-validation and variant interpretation of a next generation sequencing panel for lymphoid cancer prognostication.Journal of clinical pathology · 2025Article
- The Role of Artificial Intelligence and Radiomics in the Management of Lymphomas by PET/CT: The Clairvoyance in Clinic.Cancer management and research · 2025Review
- Development and validation of novel models based on clonality immunoglobulin gene rearrangement for evaluation of bone marrow involvement and prognostic prediction in patients with diffuse large B-cell Lymphoma: a multicenter retrospective study.Frontiers in immunology · 2025Article
- Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma.Haematologica · 2024Article
- Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting.International journal of molecular sciences · 2024Article
- Leukemic presentation and progressive genomic alterations of MCD/C5 diffuse large B-cell lymphoma (DLBCL).Cold Spring Harbor molecular case studies · 2023Article
- Role of RNA Splicing Mutations in Diffuse Large B Cell Lymphoma.International journal of general medicine · 2023Review
- Article
- Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.Translational cancer research · 2021Article
- Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.Cancer science · 2020Article
- Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.Frontiers in oncology · 2020Article
- [Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
Corrections and comments
- Erratum for
Authors and funding
46 authors.
Bjoern ChapuyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Chip StewartBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Andrew J DunfordBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Jaegil KimBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Atanas KamburovBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Robert A ReddBiostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mike S LawrenceHarvard Medical School, Boston, MA, USA.
Margaretha G M RoemerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Amy J LiBoston University School of Medicine, Section of Computational Biomedicine, Boston, MA, USA.
Marita ZiepertInstitute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany.
Annette M StaigerDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0000-0002-5896-3200
Jeremiah A WalaBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6591-1620
Matthew D DucarDana-Farber Cancer Institute, Center for Cancer Genome Discovery, Boston, MA, USA.
Ignaty LeshchinerBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8942-9265
Ester RheinbayBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Amaro Taylor-WeinerBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Caroline A CoughlinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Julian M HessBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Chandra S PedamalluBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Dimitri LivitzBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2528-1446
Daniel RosebrockBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Mara RosenbergBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Adam A TracyBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Heike HornDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tuebingen, Tuebingen, Germany.
Paul van HummelenDana-Farber Cancer Institute, Center for Cancer Genome Discovery, Boston, MA, USA.
Andrew L FeldmanMayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5009-4808
Brian K LinkUniversity of Iowa, Iowa City, IA, USA.
Anne J NovakMayo Clinic, Rochester, MN, USA.
James R CerhanMayo Clinic, Rochester, MN, USA.
Thomas M HabermannMayo Clinic, Rochester, MN, USA.
Reiner SiebertDepartment for Human Genetics, University Ulm, Ulm, Germany.
Andreas RosenwaldDepartment of Pathology, University of Würzburg, Würzburg, Germany.
Aaron R ThornerDana-Farber Cancer Institute, Center for Cancer Genome Discovery, Boston, MA, USA.
Matthew L MeyersonHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9133-8108
Todd R GolubHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0113-2403
Rameen BeroukhimHarvard Medical School, Boston, MA, USA.
Gerald G WulfDepartment of Hematology and Oncology, Georg-August University Göttingen, Göttingen, Germany.
German OttDepartment of Clinical Pathology, Robert-Bosch Krankenhaus, Stuttgart, Germany.
Scott J RodigHarvard Medical School, Boston, MA, USA.
Stefano MontiBoston University School of Medicine, Section of Computational Biomedicine, Boston, MA, USA.
Donna S NeubergHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2566-3145
Markus LoefflerInstitute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany.
Michael PfreundschuhDepartment of Medicine I, Saarland University, Homburg, Germany.
Lorenz TrümperDepartment of Hematology and Oncology, Georg-August University Göttingen, Göttingen, Germany.
Gad GetzHarvard Medical School, Boston, MA, USA. gadgetz@broadinstitute.org.ORCID http://orcid.org/0000-0002-0936-0753
Margaret A ShippDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. margaret_shipp@dfci.harvard.edu.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the version of this article originally published, an asterisk was omitted from Fig. 1a. The asterisk has been added to the figure. Additionally, a "NOTCH2" label was erroneously included in Fig. 4a. The label has been removed. The errors have been corrected in the PDF and HTML versions of this article.
Identifiers
PMID
29955182What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.